Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a ...

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, ...

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

The new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a ...

Immune drugmaker TRex Bio has priced a $117 million initial public offering, joining the ranks of nearly two dozen biotechnology companies that have done so in 2026. TRex sold 8,333,334 shares at $14 ...

The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...

The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...

Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...

A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...

Cerevance plans to meet with the FDA to determine next steps for a new kind of medicine known as solengepras, now that it has ...

The fundraise is the firm’s largest to date, providing a lift for a European biotech industry that’s fallen further behind ...